SRS-MHT-44

SRS-MHT-44 is a proprietary formulation of modified citrus pectin (MCP) being developed by Clinical Research Australia for the treatment of post-acute sequelae of SARS-CoV-2 infection, commonly referred to as Long COVID. The therapeutic mechanism of SRS-MHT-44 involves the inhibition of galectin-3, a beta-galactoside-binding lectin that plays a pivotal role in the regulation of inflammatory responses and fibrotic tissue remodeling. Elevated levels of galectin-3 have been implicated in the persistent inflammatory state and multi-organ complications associated with Long COVID. By binding to the carbohydrate-recognition domain of galectin-3, SRS-MHT-44 aims to block its pro-inflammatory signaling, thereby potentially alleviating symptoms such as fatigue, brain fog, and respiratory distress in affected individuals.

Other names

Modified Citrus PectinMCP